DEFM14A: Aptose Biosciences to be Acquired by Hanmi Pharma for C$2.41/Share

Aptose Biosciences Inc. shareholders will vote on a C$2.41 per share cash acquisition by HS North America Ltd., a subsidiary of Hanmi Pharmaceutical Co. Ltd., following a board recommendation.

Summary

• HS North America Ltd., a wholly-owned subsidiary of Hanmi Pharmaceutical Co. Ltd., proposes to acquire all issued and outstanding shares of Aptose Biosciences Inc. for C$2.41 per share in cash.
• The acquisition will be completed via a statutory plan of arrangement under the Business Corporations Act (Alberta) (ABCA).
• A special meeting of shareholders is scheduled for March 31, 2026, to vote on a resolution to continue Aptose from the Canada Business Corporations Act (CBCA) to the ABCA, and a special resolution to approve the Arrangement.
• The Board of Directors, based on the unanimous recommendation of a special committee of independent directors (Transaction Committee), unanimously approved the Arrangement and recommends shareholders vote FOR both resolutions.
• Locust Walk Securities, LLC, Aptose's financial advisor, delivered a Formal Valuation concluding the fair market value of the shares was in the range of C$1.00 to C$5.08 per share as of November 18, 2025.
• Locust Walk also provided a Fairness Opinion, stating that the C$2.41 per share consideration is fair, from a financial point of view, to shareholders (excluding Hanmi and its affiliates).
• Upon completion, Aptose will become a wholly-owned indirect subsidiary of Hanmi, its shares will be delisted from the TSX and OTC Markets, and it will cease to be a reporting issuer.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a highly positive outcome for Aptose shareholders, given the company's severe financial distress and the strong premium offered compared to market price and industry precedents, providing a clear exit from a precarious financial situation.

Positives

• The C$2.41 per share cash consideration provides shareholders with certainty, immediate value, and liquidity.
• The offer represents a premium of approximately 28% to the 30-day volume weighted average price of C$1.88 per share on the TSX.
• The Board and Transaction Committee unanimously recommended the Arrangement, supported by a Fairness Opinion from an independent financial advisor.
• The acquisition is not subject to a financing condition, reducing uncertainty regarding deal completion.
• The Purchaser has committed to supporting the uninterrupted expanded development of tuspetinib in the TUSCANY clinical study, aligning with Aptose's mission and patient interests.
• Existing employment agreements and total compensation for employees will be honored for 12 months following the Effective Time, and retention/deferred bonuses will be paid.

Negatives

• Aptose faces significant liquidity and capital constraints, with a high likelihood of insolvency in the absence of the Arrangement.
• The company reported a negative book value per share of -$7.62 as of September 30, 2025, and recurring net losses ($25.43 million in FY2024, $17.71 million for nine months ended September 30, 2025).
• Aptose's shares were delisted from the Nasdaq Stock Market on April 2, 2025, due to non-compliance with minimum equity requirements.
• If the Arrangement is not completed under certain circumstances, Aptose will be required to immediately implement Alternative CCAA Proceedings, which could result in no consideration for shareholders.
• Certain directors and executive officers have interests in the Arrangement (severance, deferred bonuses, retention bonuses) that are different from, or in addition to, the interests of general shareholders.
• Aptose will incur costs related to the Arrangement, and may be required to pay an expense fee of C$300,000 to the Purchaser in certain termination scenarios.
• Shareholders will no longer hold an interest in Aptose and will forgo any future increase in value that might result from the company's long-term plans.

Risks

• Completion of the Arrangement is subject to a number of conditions, including shareholder and regulatory approvals, which may not be satisfied or waived.
• Substantial delays in obtaining required approvals could prevent the completion of the Arrangement.
• The announcement and dedication of substantial resources to the Arrangement could negatively impact Aptose's current business relationships and operations if the deal is not completed.
• Failure to complete the Arrangement could materially negatively impact the trading price of Aptose's shares.
• If the Arrangement Agreement is terminated in certain circumstances, Aptose will be required to immediately implement Alternative CCAA Proceedings, potentially resulting in no consideration for shareholders.
• The C$300,000 Expense Fee, payable in certain termination scenarios, may discourage other parties from proposing alternative transactions.
• The Arrangement Agreement does not provide for a reverse break fee if the Purchaser fails to deposit the consideration.
• The Purchaser has the right to terminate the Arrangement Agreement if more than 5% of issued and outstanding shares exercise Dissent Rights.
• Restrictions imposed by the Arrangement Agreement on Aptose's business conduct during the interim period may prevent the company from pursuing attractive business opportunities.
• The Arrangement will generally be a taxable transaction for shareholders, requiring them to pay taxes on any taxable gains.
• Applicable tax authorities may not agree with the tax discussions included in the Proxy Statement.
• Aptose expects to be a Passive Foreign Investment Company (PFIC), which may result in adverse U.S. federal income tax consequences for U.S. Shareholders.

Future Outlook

The Purchaser intends to support the uninterrupted expanded development of tuspetinib in the TUSCANY clinical study, creating value for patients currently enrolled. Following the Arrangement, Aptose will cease to be a public company, delist its shares from the TSX and OTC Markets, and deregister its securities under the Exchange Act, which is expected to reduce administrative and financial burdens.

Management Comments

• "The Board, on recommendation of the Transaction Committee, consideration of the Formal Valuation and the Fairness Opinion, and based upon its own investigations, has unanimously approved the Arrangement and the terms of the Arrangement Agreement and has determined that the Arrangement is in the best interests of Aptose and the Shareholders (excluding Shares held by the Parent and its affiliates). Accordingly, the Board unanimously recommends that you vote FOR the Continuance Resolution and the Arrangement Resolution at the Meeting."
• "The Board is proposing the Arrangement because, after consultation with its financial and legal advisors and careful consideration of various factors, and upon the unanimous recommendation of the Transaction Committee, the Board has unanimously determined that the Arrangement is fair to the Shareholders (other than the Parent and its affiliates or the Corporations affiliates) and that the Arrangement is in the best interests of the Corporation."

Industry Context

StockSavvy.ai notes that this acquisition represents a strategic move by Hanmi Pharmaceutical to acquire a clinical-stage biotechnology company, Aptose, which specializes in oncology, particularly hematology. The acquisition of Aptose, a company facing significant liquidity challenges and a Nasdaq delisting, by an R&D-oriented biopharmaceutical company like Hanmi, highlights a trend of larger, financially stable players acquiring distressed smaller biotechs for their promising pipeline assets (e.g., tuspetinib). This allows the acquirer to leverage existing R&D infrastructure and potentially accelerate drug development while providing a necessary exit for the financially constrained target.

Comparison to Industry Standards

• The offered price of C$2.41 per share represents a 28% premium over Aptose's 30-day volume weighted average price (VWAP) of C$1.88 on the TSX.
• Locust Walk's precedent transaction analysis for 'Phase 1 to 2 Therapeutic Area Agnostic, Distressed M&A Transactions' showed an average upfront premium of 21% and a median of 16% to the 30-day VWAP. The 28% premium offered to Aptose is above this average/median, suggesting a favorable outcome for shareholders of a distressed company.
• For 'Phase 1 to 2 Solid Tumor and Hematological/Oncology, M&A Transactions,' the average upfront premium was 9.7% and the median was also 9.7%. The 28% premium for Aptose significantly exceeds these benchmarks, further indicating a strong offer given the company's financial state.
• The fair market value range of C$1.00 to C$5.08 per share determined by Locust Walk's Formal Valuation, which included a dilution-adjusted DCF analysis (low $0.28, high $1.28 USD/share) and precedent transaction comparisons (upfront premiums $1.44-$1.74 USD/share, total deal value premiums $1.50-$4.69 USD/share), positions the C$2.41 (approximately $1.77 USD) offer within the higher end of the dilution-adjusted DCF and within the range of precedent transaction upfront premiums.

Corporate Governance

Legal Proceedings

• No material legal proceedings are currently in effect or ongoing, or to the knowledge of the Corporation, pending or threatened against Aptose or its subsidiaries that would have a Material Adverse Effect or prevent/delay the Arrangement.
• No bankruptcy, liquidation, dissolution, winding-up, or other similar proceeding is pending or in progress, or threatened against Aptose or its subsidiaries.
• No outstanding Order exists that would have a Material Adverse Effect or prevent/delay the consummation of the Arrangement.
• Any Transaction Litigation (proceedings by third parties against Aptose or its directors/officers related to the Arrangement) will be notified to the Purchaser, who will have the opportunity to participate in defense and consultation.

Related Party Transactions

• Hanmi Pharmaceutical Co. Ltd. (Parent) is a significant shareholder, beneficially owning approximately 19.93% of outstanding shares as of the Record Date.
• Aptose entered into a Tuspetinib Licensing Agreement with Hanmi on November 4, 2021, granting exclusive worldwide rights to tuspetinib.
• A Supply Agreement with Hanmi for additional production of drug substance and product for tuspetinib clinical development was entered into in 2022.
• A Loan Agreement with Hanmi on August 27, 2024, provided Aptose with up to $10 million, secured by Aptose's personal property and subsidiary guarantees.
• A Debt Conversion and Interest Payment Agreement with Hanmi on March 18, 2025, converted $1.5 million of Hanmi's indebtedness into 409,063 Common Shares.
• An Amended and Restated Investors Rights Agreement was entered into with Hanmi, providing Hanmi with certain shareholder rights, including board nomination rights if ownership exceeds 10%.
• A Loan Agreement with Hanmi on June 20, 2025, provided an uncommitted facility for up to $8.5 million for tuspetinib development and operations.
• An Amended and Restated Loan Agreement with Hanmi on September 22, 2025, provided an additional uncommitted facility for up to $11.9 million.
• A short-term, interest-free advance of $100,000 was provided by Aptose's CEO on June 17, 2025, and repaid on June 26, 2025.
• Retention bonus agreements are in place with executive officers and vice-presidents, payable upon a change of control.
• Deferred bonus payments for 2024 for all employees, including executive officers, will become payable upon the closing of the Arrangement.

Stakeholder Impact

• Shareholders: Will receive C$2.41 cash per share, providing liquidity and a premium over recent trading prices, but will forgo future potential value from Aptose's long-term plans. Registered shareholders have dissent rights to demand fair value.
• Employees: Existing employment agreements will be honored, and total compensation will be substantially similar for 12 months post-Effective Time. Retention and deferred bonuses will be paid.
• Customers/Patients: The Purchaser is committed to supporting the uninterrupted expanded development of tuspetinib in the TUSCANY clinical study, which is positive for patients relying on Aptose's pipeline.
• Creditors: The Arrangement provides a resolution for Aptose's significant indebtedness, particularly to Hanmi. If the Arrangement fails, Alternative CCAA Proceedings could impact creditors' recovery.

Next Steps

• Special Meeting of Shareholders on March 31, 2026, to vote on the Continuance Resolution and the Arrangement Resolution.
• Aptose will apply to the Court for the Final Order approving the Arrangement after shareholder approval.
• Filing of Articles of Arrangement with the Registrar under the ABCA to give effect to the Arrangement.
• Delisting of Shares from the TSX and OTC Markets following the completion of the Arrangement.
• Application to cease being a reporting issuer under applicable Canadian securities laws and deregister securities under the Exchange Act.
• The Purchaser will cause Aptose to honor all obligations under employment agreements with current employees and provide comparable total compensation for 12 months following the Effective Time.
• Aptose will use reasonable best efforts to obtain an agreement from CrystalGenomics, Inc. confirming the termination of the CG-806 license and providing for a customary mutual release of claims.
• Aptose will use reasonable best efforts to obtain Support and Voting Agreements from shareholders holding no less than 5% of the Shares within ten days following the mailing of the Circular.

Key Dates

Recommendation

The filing details a definitive acquisition offer at C$2.41 per share, representing a significant premium for a company facing severe financial distress and delisting. The Board unanimously recommends shareholders vote for the Arrangement, which implies accepting the cash offer. For existing shareholders, this represents a favorable exit from a high-risk investment. For new investors, the opportunity for long-term growth in Aptose as an independent entity is being eliminated, making 'sell' (by accepting the offer) the logical action for current holders, and 'na' for new investment in the company itself.

Keywords

Aptose Biosciences, Hanmi Pharmaceutical, HS North America, Acquisition, Merger, Biotechnology, Oncology, Tuspetinib, SEC Filing, Proxy Statement, Plan of Arrangement, Shareholder Vote, Delisting, Going Concern, Financial Distress, Biopharma M&A